ProQR Therapeutics N.V. (NASDAQ:PRQR) Short Interest Up 80.2% in October

ProQR Therapeutics N.V. (NASDAQ:PRQR) was the target of a significant increase in short interest during the month of October. As of October 15th, there was short interest totaling 2,090,000 shares, an increase of 80.2% from the September 30th total of 1,160,000 shares. Currently, 2.2% of the company’s shares are sold short. Based on an average daily trading volume, of 430,800 shares, the short-interest ratio is presently 4.9 days. Based on an average daily trading volume, of 430,800 shares, the short-interest ratio is presently 4.9 days. Currently, 2.2% of the company’s shares are sold short.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Osaic Holdings Inc. boosted its holdings in shares of ProQR Therapeutics by 59.6% in the second quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 4,500 shares during the period. Vontobel Holding Ltd. acquired a new position in shares of ProQR Therapeutics in the first quarter valued at approximately $48,000. OneDigital Investment Advisors LLC boosted its holdings in shares of ProQR Therapeutics by 45.5% in the first quarter. OneDigital Investment Advisors LLC now owns 40,000 shares of the biopharmaceutical company’s stock valued at $53,000 after buying an additional 12,500 shares during the period. Persistent Asset Partners Ltd acquired a new position in shares of ProQR Therapeutics in the first quarter valued at approximately $64,000. Finally, Jane Street Group LLC boosted its holdings in shares of ProQR Therapeutics by 699.3% in the first quarter. Jane Street Group LLC now owns 91,120 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 79,720 shares during the period. Institutional investors and hedge funds own 32.65% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on PRQR shares. Zacks Research downgraded shares of ProQR Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, October 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of ProQR Therapeutics in a research note on Wednesday, October 8th. Chardan Capital reissued a “buy” rating and set a $4.00 price target on shares of ProQR Therapeutics in a research note on Friday, August 8th. Finally, Evercore ISI reissued an “outperform” rating on shares of ProQR Therapeutics in a research note on Friday, July 11th. Seven research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $7.14.

ProQR Therapeutics Stock Performance

Shares of NASDAQ:PRQR opened at $2.75 on Monday. ProQR Therapeutics has a 52 week low of $1.07 and a 52 week high of $4.21. The company has a market capitalization of $289.33 million, a PE ratio of -5.98 and a beta of 0.16. The company has a 50 day moving average price of $2.39 and a two-hundred day moving average price of $2.08.

ProQR Therapeutics (NASDAQ:PRQR) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.06). The firm had revenue of $4.33 million during the quarter, compared to the consensus estimate of $5.01 million. ProQR Therapeutics had a negative net margin of 238.52% and a negative return on equity of 61.25%. On average, sell-side analysts forecast that ProQR Therapeutics will post -0.31 earnings per share for the current year.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).